You are here: Industry Insights > ovarian cancer

News List

Almac Discovery granted Orphan Drug Designation for ALM201 programme in ovarian cancer cphi-online
July 10, 2017
ALM201 is a therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL.
Breakthrough treatment for ovarian cancer displays promising results pharmafile
June 06, 2017
A treatment that specifically targets ovarian cancer cells has shown that half of women who took the drug experienced shrinking of their tumours. In the cases where women possessed a particular molecular target, seven out of ten women were found to respon
A new sensitive technique for detecting ovarian tumours biospectrumasia
April 14, 2017
Ovarian cancer is mostly diagnosed at such late stages that patients' survival rates are poor.
Tesaro announces FDA approval of Zejula for women with recurrent ovarian cancer cphi-online
March 31, 2017
Tesaro has announced that the FDA has approved Zejula (niraparib) for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response (CR or PR) to platinumbased
Lynparza Phase III data demonstrates progression-free survival in ovarian cancer europeanpharmaceuticalreview
March 20, 2017
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive...
AstraZeneca's ovarian cancer drug Lynparza demonstrates PFS benefit as maintenance therapy in Phase firstwordpharma
March 15, 2017
Study showed that AstraZeneca's PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) in certain patients with BRCA-mutated ovarian cancer, compared with placebo in the maintenance setting.
Know the Risks, Warning Signs of Ovarian Cancer drugs.com
January 19, 2017
Women need to be aware their risk for ovarian cancer increases with age. Half of all cases affect women age 63 or older, according to specialists at Fox Chase Cancer Center in Philadelphia.
Neovacs to Collaborate with the Sunnybrook Research Inst. contractpharma
January 09, 2017
Will focus on preclinical development of VEGF Kinoid to treat colorectal cancer and ovarian cancer.

Previous page 1 2 3 4 5 6 7 8 Next page